Faeth Therapeutics Plummets 42%. What Investors Are Getting Wrong, According To Analysts.
Biotech stock Faeth Therapeutics crashed Monday as investors questioned the effectiveness of its endometrial cancer drug.
The post Faeth Therapeutics Plummets 42%. What Investors Are Getting Wrong, According To Analysts. appeared first on Investor's Business Daily .